Latest & greatest articles for hypertension

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hypertension or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hypertension and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hypertension

1461. Hypertensive responses induced by phenylpropanolamine in anorectic and decongestant preparations. (Abstract)

Hypertensive responses induced by phenylpropanolamine in anorectic and decongestant preparations. The acute effects of a single capsule of each of two phenylpropanolamine-containing preparations were determined in a group of healthy young adults, by means of a double-blind comparison with matching placebo preparations. Supine diastolic blood-pressure rose to 100 mm Hg or more in 12 out of 37 subjects taking an anorectic preparation ('Trimolets'; 85 mg phenylpropanolamine per capsule) and in 4 (...) out of 34 subjects taking a decongestant preparation ('Contac 500'; 50 mg phenylpropanolamine per capsule). 20 of the subjects taking trimolets reported adverse side effects. The frequency and extent of the hypertensive response to high-dose phenylpropranolamine-containing preparations suggest that clinical use of such preparations should be reviewed and that their availability without prescription may not be appropriate.

1980 Lancet Controlled trial quality: uncertain

1462. Propranolol--a medical treatment for portal hypertension? (Abstract)

Propranolol--a medical treatment for portal hypertension? Continuous, oral administration of propranolol at doses which reduced the heart-rate by 25% produced a sustained decrease in portal venous pressure in cirrhotic patients with portal hypertension. This effect of propranolol might be useful in preventing recurrent bleeding due to ruptured oesophageal varices in patients with portal hypertension.

1980 Lancet Controlled trial quality: uncertain

1463. Work-site treatment of hypertension by specially trained nurses. A controlled trial. (Abstract)

Work-site treatment of hypertension by specially trained nurses. A controlled trial. The clinical efficacy of using specially trained nurses to treat hypertension at the patient's place of work was compared in a controlled trial with management by the patient's family doctor. The 457 study participants were selected from 21 906 volunteers in industry and government whose blood-pressure was screened. The nurses were allowed to prescribe and change drug therapy at the work site without prior (...) physician approval. Patients randomly allocated to receive care at work were significantly more likely to be put on antihypertensive medications (94.7% vs 62.7%, to reach goal blood-pressure in the first six months (48.5% vs 27.5%), and to take the drugs prescribed (67.6% vs 49.1%). Only 6% of patients were dissatisfied with the care provided by the nurses. Thus provision of care at work by specially tranined nurses was well accepted and resulted in significantly improved blood-pressure control

1979 Lancet Controlled trial quality: uncertain

1464. Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group. (Abstract)

Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group. The Hypertension Detection and Follow-up Program (HDFP), in a community-based, randomized controlled trial involving 10,940 persons with high blood pressure (BP), compared the effects on five-year mortality of a systematic antihypertensive treatment program (Stepped Care (...) [SC]) and referral to community medical therapy (Referred Care [RC]). Participants, recruited by population-based screening of 158,906 people aged 30 to 69 years in 14 communities througout the United States, were randomly assigned to SC or RC groups within each center and by entry diastolic blood pressure (DBP) (90 to 104, 105 to 114, and 115 + mm Hg). Over the five years of the study, more than two thirds of the SC participants continued to receive medication, and more than 50% achieved BP

1979 JAMA Controlled trial quality: uncertain

1465. Five-year findings of the hypertension detection and follow-up program. II. Mortality by race-sex and age. Hypertension Detection and Follow-up Program Cooperative Group. (Abstract)

Five-year findings of the hypertension detection and follow-up program. II. Mortality by race-sex and age. Hypertension Detection and Follow-up Program Cooperative Group. Data are reported for four race-sex and three age subgroups of the Hypertension Detection and Follow-up Program (HDFP). Throughout the HDFP trial, for black men, black women, white men, and white women and for persons aged 30 to 49, 50 to 59, and 60 to 69 years at entry, control of blood pressure was consistently better

1979 JAMA Controlled trial quality: uncertain

1466. Double-blind trial of antihypertensive effect of chlorothiazide in severe renal failure. (Abstract)

Double-blind trial of antihypertensive effect of chlorothiazide in severe renal failure. A randomised double-blind crossover trial was done to assess the efficacy of chlorothiazide as an antihypertensive drug in patients with severe renal failure. There was a significant reduction in standing (mean drop 13/6 mm Hg) and supine (mean drop 13/5 mm Hg) blood-pressure, without postural hypotension. Chlorothiazide has a place in the management of hypertension in patients with severe renal failure (...) and its antihypertensive effect is probably due to a change in peripheral vascular resistance and not to volume contraction.

1979 Lancet

1467. Comparative effects of ticrynafen and hydrochlorothiazide in the treatment of hypertension. (Abstract)

Comparative effects of ticrynafen and hydrochlorothiazide in the treatment of hypertension. Two dose levels of ticrynafen, a new uricosuric diuretic, and of hydrochlorothiazide were randomly assigned, double-blind to 240 men with initial diastolic blood pressures in the range of 95 to 114 mm Hg. A dose of 500 mg of ticrynafen once daily exerted an antihypertensive effect comparable to that of 50 or 100 mg of hydrochlorothiazide. Whereas serum uric acid levels rose in patients treated (...) with hydrochlorothiazide, they fell markedly in those receiving ticrynafen. Otherwise, both diuretics produced similar chemical changes in serum. Patients tolerated ticrynafen as well as they did hydrochlorothiazide over a period of six months of observation, and there was no evidence of serious toxicity or loss of therapeutic effect with ticrynafen. This antihypertensive agent, in appropriate doses, appears to be as effective and well tolerated as hydrochlorothiazide, and in addition ticrynafen prevents hyperuricemia.

1979 NEJM Controlled trial quality: uncertain

1468. Ticrynafen and hydrochlorothiazide. A double-blind study of antihypertensive properties with an open crossover. (Abstract)

Ticrynafen and hydrochlorothiazide. A double-blind study of antihypertensive properties with an open crossover. Twenty-eight patients completed a double-blind study of the antihypertensive effects of ticrynafen compared with those of hydrochlorothiazide. The results of blood pressure reduction were comparable in the two groups. After six months, 12 patients were crossed over to ticrynafen therapy from hydrochlorothiazide. They maintained their blood pressure reduction. The most striking (...) difference between the two groups was in the uric acid response. The uric acid level in the patients receiving hydrochlorothiazide therapy rose from a baseline of 5.9 to 7.5 mg/dL (normal range, 3.0 to 8.0 mg/dL). The uric acid level of those patients receiving ticrynafen therapy decreased from a baseline of 6.4 mg/dL to a low of 3.3 mg/dL. In view of ticrynafen's appreciable antihypertensive and uric-acid-lowering effects, it appears to be a useful new antihypertensive drug.

1979 JAMA Controlled trial quality: uncertain

1469. Biochemical and haematological changes induced by tienilic acid combined with propranolol in essential hypertension. (Abstract)

Biochemical and haematological changes induced by tienilic acid combined with propranolol in essential hypertension. Sixteen patients with moderate essential hypertension completed a double-blind crossover trial with four treatment periods each of 6 weeks. They received in random order: placebo; tienilic acid 250 mg/day; propranolol 80 mg twice daily; and tienilic acid 250 mg/day combined with propranolol 80 mg twice daily. Average blood-pressure in the lying position was 22.6/13.1 kPa (169/98 (...) mm Hg) on placebo; 21.0/12.5 (157/94) on tienilic aicd; 21.2/12.0 (159/90) on propranolol, and 18.9/11.5 (142/86) on tienilic acid combined with propranolol. The effects of tienilic acid and propranolol on blood-pressure were additive and there were no statistically significant interactions. Tienilic acid significantly reduced serum-urate from 0.33 to 0.18 mmol/l and induced hypokalaemia which was corrected by propranolol. Basophil count and haemoglobin were lower after tienilic acid treatment

1979 Lancet

1470. Hypertension treated by salt restriction. (Abstract)

Hypertension treated by salt restriction. 31 patients with a diastolic blood-pressure between 95 and 109 mm Hg have been treated for two years with a regimen involving a moderate restriction of salt in the diet. The results are compared with those in a control group and in a drug-treated group. Salt restriction has reduced the diastolic blood-pressure by 7.3+/-1.6 mm Hg, a result similar to that in patients treated with antihypertensive drugs. In the untreated group the diastolic blood-pressure (...) rose by 1.8+/-1.1 mm Hg. Most patients did not achieve the desired amount of salt restriction and a stricter adherence to the diet might have caused further falls in blood-pressure. Excessive salt intake is probably a major cause of the epidemic of hypertension in "civilised" countries and a reduction in salt intake may help to control the epidemic. In persons with a diastolic blood-pressure between 90 and 105 mm Hg salt restriction should be tried before drugs.

1978 Lancet

1471. Glucose intolerance during diuretic therapy. Results of trial by the European Working Party on Hypertension in the Elderly. (Abstract)

Glucose intolerance during diuretic therapy. Results of trial by the European Working Party on Hypertension in the Elderly. 119 elderly, hypertensive patients were followed-up for 1 year and 48 for 2 years in a double-blind, randomised, controlled trial in which they received either placebo or 25-50 mg hydrochlorothiazide and 50-100 mg of triamterene daily. Half of the active treatment group also received 250 mg to 2 g methyldopa daily. After 2 years the active treatment group had an average (...) increase in fasting blood-sugar of 9.6 mg/dl compared with an average fall of 3.1 mg in the placebo group (p less than 0.001). Blood-glucose rose by an average of 26.6 mg/dl in the active group when determined 1 hour after 50 g oral glucose and decreased by an average of 5.3 mg/dl in patients who had been on placebo for two years (p less than 0.05). The hyperglycaemic effect of diuretics appeared to be related to potassium loss since, in both groups, impairment of glucose tolerance was most marked

1978 Lancet

1472. Effect of weight loss without salt restriction on the reduction of blood pressure in overweight hypertensive patients. (Abstract)

Effect of weight loss without salt restriction on the reduction of blood pressure in overweight hypertensive patients. Overweight patients with uncomplicated essential hypertension were followed up biweekly for six months: 24 not receiving antihypertensive-drug therapy (Group I) and 83 on regular but inadequate (despite drug manipulation) antihypertensive-drug therapy (Group II). All patients in Group I and 57 randomly selected patients from group II (IIa) participated in a weight-reduction (...) program. The remaining 26 from Group II (IIb) did not receive a dietary program. Salt intake was in the normal range in all three groups. All patients on the dietary program lost at least 3 kg (mean, 10.5 kg), and all but two showed a meaningful reduction in blood pressure; 75 per cent of Group I and 61 per cent of Group IIa returned to normal blood pressure. The weight and blood-pressure reductions were highly significant (P less than 0.001), were present in both sexes and all ages, and were directly

1978 NEJM Controlled trial quality: uncertain

1473. Increased absenteeism from work after detection and labeling of hypertensive patients. (Abstract)

in the general employee population during this period. The main factors associated with increased absenteeism were becoming aware of the condition (P less than 0.01) and low compliance with treatment (P less than 0.001). Subsequent absenteeism among patients unaware of their hypertension before screening was not related to the degree of hypertension, whether the worker was started on therapy, the degree of blood-pressure control achieved or exposure to attempts to promote compliance. These results have major (...) implications for hypertension screening programs, especially since absenteeism rose among those previously unaware of their condition, regardless of whether antihypertensive therapy was begun.

1978 NEJM Controlled trial quality: uncertain

1474. Furosemide compared with hydrochlorothiazide. Long-term treatment of hypertension. (Abstract)

Furosemide compared with hydrochlorothiazide. Long-term treatment of hypertension. In a double-blind crossover study, the effectiveness of furosemide, 40 mg twice daily, was compared with hydrochlorothiazide, 50 mg twice daily, in hypertensive patients. Both hydrochlorothiazide and furosemide significantly reduced blood pressure (BP) during three months of therapy. However, the fall in BP was consistently greater with hydrochlorothiazide than with furosemide, although the difference (...) was significant only with respect to systolic BP. The somewhat greater antihypertensive effectiveness of hydrochlorothiazide may be related to its longer action permitting a more continuous diuretic effect and, hence, maintenance of reduced extracellular fluid volume throughout the 24-hour period.

1978 JAMA Controlled trial quality: uncertain

1475. Comparison of tienilic acid with cyclopenthiazide in hyperuricaemic hypertensive patients. (Abstract)

Comparison of tienilic acid with cyclopenthiazide in hyperuricaemic hypertensive patients. Tienilic acid, a diuretic with uricosuric properties, was compared with cyclopenthiazide, in an open, random-order, within-patient crossover study (3 months on each drug) in 36 hyperuricaemic hypertensive patients. All were on an established dose of cyclopenthiazide; most were also on a beta-blocker which they continued to take in their usual dose. A mean dose of 210 mg of tienilic acid gave the same (...) antihypertensive and diuretic effect as a mean dose of 0.41 mg of cyclopenthiazide. Serum uric acid was very much lower when patients were on tienilic acid (0.29 mmol/l) than on cyclopenthiazide (0.50 mmol/l). Apart from slightly higher serum-chloride and serum-urea during the period on tienilic acid, no major differences in serum-electrolytes, renal-function tests, glucose tolerance, and fasting lipids were observed. Audiometric tests showed that tienilic acid was not ototoxic. S.G.O.T. and S.G.P.T. rose

1978 Lancet

1476. Modification of antihypertensive effect of beta-adrenoceptor-blocking agents by inhibition of endogenous prostaglandin synthesis. (Abstract)

beta-blocker phases (P less than 0-01). The changes in systolic blood-pressure and pulse-rate were not significant. These preliminary results suggest that the antihypertensive effect of these two beta-blockers in some hypertensive patients may be related to the endogenous prostaglandin system. (...) alone. Mean supine diastolic blood-pressure rose from 82 +/- 2 mm Hg in the first beta-blocker phase to 98 +/- 3 mm Hg in the placebo phase, remained elevated (96 +/- 3 mm Hg) in the beta-blocker-plus-indomethacin phase, and fell to 83 +/- 3 mm Hg in the last beta-blocker phase. Diastolic blood-pressure values obtained in the beta-blocker-plus-indomethacin phase were not significantly different from those obtained in the placebo phase but were significantly different from the values measured in both

1977 Lancet

1477. Minoxidil in resistant hypertension. (Abstract)

Minoxidil in resistant hypertension. Minoxidil in combination with propranolol and diuretics controlled the blood-pressure in a group of hypertensive patients who were resistant to treatment with large doses of standard drugs. The main problem was fluid retention but subjective side-effects were fewer than in a comparable group on other drugs.

1977 Lancet Controlled trial quality: uncertain

1478. Evaluation of beta blockade bendrofluazide, and prazosin in severe hypertension. (Abstract)

Evaluation of beta blockade bendrofluazide, and prazosin in severe hypertension. 20 patients with severe essential hypertension (average blood-pressure 211/123 mm Hg) had an inadequate fall in blood-pressure with beta blockade alone. They were given in random order either 5 and then 10 mg of bendrofluazide a day or prazosin 2 mg three times daily rising to 5 mg if required. The trial was a within-patient comparison of the two drug regimens. 10 patients who did not achieve a satisfactory fall (...) serum-potassium levels fell below 3-6 mmol/l in half the patients within the first two weeks of treatment. It is concluded that patients with essential hypertension already treated with beta blockade who need an additional agent will get a further fall in blood-pressure with 5 mg of bendrofluazide. Prazosin appears to be a potent and appropriate third agent.

1977 Lancet

1479. Clinical study of ticrynafen. A new diuretic, antihypertensive, and uricosuric agent. (Abstract)

Clinical study of ticrynafen. A new diuretic, antihypertensive, and uricosuric agent. In a double-blind study, 20 hypertensive patients were randomly assigned to a six-week regimen of either ticrynafen or hydrochlorothiazide. Blood pressure was significantly reduced with both medications, although most patients required an increase in dosage from 250 to 500 mg ticrynafen daily. Whereas the serum uric acid level rose moderately in the hydrochlorothiazide-treated patients, it fell strikingly (...) to less than half of the pretreatment level in patients treated with ticryafen. Body weight decreased slightly in both groups, as did serum potassium levels. Blood urea nitrogen and serum creatinine levels rose slightly in both groups. The magnitude of these changes was not significantly different between the two groups. Use of ticryafen was well tolerated. Ticryafen appears to be a useful new antihypertensive agent because of its unique combination of diuretic, antihypertensive, and hypouricemic

1977 JAMA Controlled trial quality: uncertain

1480. [The antihypertensive effect of a new beta-blocking drug timolol in combination with hydrochlorothiazide]. (Abstract)

[The antihypertensive effect of a new beta-blocking drug timolol in combination with hydrochlorothiazide]. 7444 1976 10 01 2013 11 21 0012-7183 92 11 1976 Duodecim; laaketieteellinen aikakauskirja Duodecim [The antihypertensive effect of a new beta-blocking drug timolol in combination with hydrochlorothiazide]. 588-96 Pyörälä K K Mattila S S Leirisalo M M Toivonen S S fin Clinical Trial English Abstract Journal Article Randomized Controlled Trial Timololin ja hydroklortiatsidin yhdistelmän (...) verenpainetta alentava vaikutus Finland Duodecim 0373207 0012-7183 0 Adrenergic beta-Antagonists 0J48LPH2TH Hydrochlorothiazide IM Adrenergic beta-Antagonists therapeutic use Adult Clinical Trials as Topic Drug Evaluation Drug Therapy, Combination Female Humans Hydrochlorothiazide therapeutic use Hypertension drug therapy Male Middle Aged 1976 1 1 1976 1 1 0 1 1976 1 1 0 0 ppublish 7444

1976 Duodecim; laaketieteellinen aikakauskirja